Alembic Pharmaceuticals Ltd: Share Price Analysis, Intrinsic Value & Fundamentals (2025)

Share Price and Basic Stock Data

Last Updated: March 9, 2025, 8:27 pm

Market Cap	16,603 Cr.
Current Price	845
High / Low	1,304/725
Stock P/E	28.0
Book Value	249
Dividend Yield	1.30 %
ROCE	13.1 %
ROE	13.3 %
Face Value	2.00
PEG Ratio	-2.33

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Alembic Pharmaceuticals Ltd

Competitors of Alembic Pharmaceuticals Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
MPS Pharmaa Ltd	6.71 Cr.	3.51	4.33/3.05		0.80	0.00 %	9.15 %	34.9 %	10.0
Gujarat Themis Biosyn Ltd	2,663 Cr.	244	390/192	50.6	20.5	0.27 %	45.0 %	33.8 %	1.00
Gujarat Terce Laboratories Ltd	53.1 Cr.	71.5	94.9/32.1	18.0	11.9	0.00 %	9.72 %	3.44 %	10.0
Gujarat Inject (Kerala) Ltd	38.0 Cr.	26.0	29.0/8.74	38.8	6.64	0.00 %	2.65 %	2.08 %	10.0
Godavari Drugs Ltd	70.4 Cr.	93.5	155/79.0	11.4	55.4	0.00 %	14.4 %	15.5 %	10.0
Industry Average	17,255.37 Cr	1,081.84		42.42	185.80	0.37%	16.00%	16.32%	6.27

All Competitor Stocks of Alembic Pharmaceuticals Ltd

Quarterly Result

Metric	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Sales	1,272	1,416	1,262	1,475	1,509	1,406	1,486	1,595	1,631	1,517	1,562	1,648	1,693
Expenses	1,030	1,268	1,255	1,244	1,274	1,203	1,287	1,387	1,364	1,257	1,325	1,409	1,433
Operating Profit	242	148	7	231	235	204	199	208	266	260	237	239	260
OPM %	19%	10%	1%	16%	16%	14%	13%	13%	16%	17%	15%	15%	15%
Other Income	19	10	1	0	0	1	12	10	3	4	2	30	10
Interest	4	7	9	12	15	14	14	16	15	11	13	19	22
Depreciation	56	123	67	68	67	74	66	68	69	69	69	71	70
Profit before tax	201	29	-67	151	154	116	130	135	185	183	157	180	178
Tax %	14%	24%	-2%	12%	21%	-31%	7%	-1%	2%	3%	14%	15%	23%
Net Profit	172	22	-66	133	122	153	121	137	180	178	135	153	138
EPS in Rs	8.74	1.12	-3.35	6.78	6.20	7.76	6.14	6.95	9.18	9.07	6.85	7.80	7.04

Last Updated: February 28, 2025, 8:42 pm

Below is a detailed analysis of the quarterly data for Alembic Pharmaceuticals Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:

For Sales, as of Dec 2024, the value is ₹1,693.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,648.00 Cr. (Sep 2024) to ₹1,693.00 Cr., marking an increase of ₹45.00 Cr..
For Expenses, as of Dec 2024, the value is ₹1,433.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,409.00 Cr. (Sep 2024) to ₹1,433.00 Cr., marking an increase of ₹24.00 Cr..
For Operating Profit, as of Dec 2024, the value is ₹260.00 Cr.. The value appears strong and on an upward trend. It has increased from 239.00 Cr. (Sep 2024) to ₹260.00 Cr., marking an increase of ₹21.00 Cr..
For OPM %, as of Dec 2024, the value is 15.00%. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 15.00%.
For Other Income, as of Dec 2024, the value is ₹10.00 Cr.. The value appears to be declining and may need further review. It has decreased from 30.00 Cr. (Sep 2024) to ₹10.00 Cr., marking a decrease of 20.00 Cr..
For Interest, as of Dec 2024, the value is ₹22.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 19.00 Cr. (Sep 2024) to ₹22.00 Cr., marking an increase of ₹3.00 Cr..
For Depreciation, as of Dec 2024, the value is ₹70.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 71.00 Cr. (Sep 2024) to ₹70.00 Cr., marking a decrease of 1.00 Cr..
For Profit before tax, as of Dec 2024, the value is ₹178.00 Cr.. The value appears to be declining and may need further review. It has decreased from 180.00 Cr. (Sep 2024) to ₹178.00 Cr., marking a decrease of 2.00 Cr..
For Tax %, as of Dec 2024, the value is 23.00%. The value appears to be increasing, which may not be favorable. It has increased from 15.00% (Sep 2024) to 23.00%, marking an increase of 8.00%.
For Net Profit, as of Dec 2024, the value is ₹138.00 Cr.. The value appears to be declining and may need further review. It has decreased from 153.00 Cr. (Sep 2024) to ₹138.00 Cr., marking a decrease of 15.00 Cr..
For EPS in Rs, as of Dec 2024, the value is 7.04. The value appears to be declining and may need further review. It has decreased from ₹7.80 (Sep 2024) to 7.04, marking a decrease of ₹0.76.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: March 7, 2025, 9:20 pm

Metric	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Sales	1,520	1,863	2,056	3,166	3,105	3,131	3,935	4,606	5,393	5,306	5,653	6,229	6,419
Expenses	1,268	1,506	1,653	2,159	2,490	2,488	3,061	3,383	3,913	4,432	4,970	5,296	5,423
Operating Profit	252	358	403	1,007	615	643	874	1,223	1,480	874	682	932	996
OPM %	17%	19%	20%	32%	20%	21%	22%	27%	27%	16%	12%	15%	16%
Other Income	4	4	4	7	2	7	9	-39	87	56	-2	28	46
Interest	15	10	4	5	5	3	18	27	16	18	50	56	65
Depreciation	35	40	44	72	83	105	115	157	183	287	275	273	279
Profit before tax	206	311	359	936	529	541	749	1,000	1,368	625	355	632	698
Tax %	20%	24%	21%	23%	23%	22%	21%	20%	19%	17%	4%	3%
Net Profit	165	236	283	720	403	413	583	801	1,146	521	342	616	604
EPS in Rs	8.77	12.49	15.01	38.20	21.39	21.89	31.00	43.97	58.33	26.50	17.40	31.33	30.76
Dividend Payout %	29%	24%	23%	9%	19%	18%	18%	23%	24%	38%	46%	35%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2013-2014	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024
YoY Net Profit Growth (%)	43.03%	19.92%	154.42%	-44.03%	2.48%	41.16%	37.39%	43.07%	-54.54%	-34.36%	80.12%
Change in YoY Net Profit Growth (%)	0.00%	-23.12%	134.50%	-198.44%	46.51%	38.68%	-3.77%	5.68%	-97.61%	20.18%	114.47%

Alembic Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:	13%
5 Years:	10%
3 Years:	5%
TTM:	5%

Compounded Profit Growth
10 Years:	10%
5 Years:	1%
3 Years:	-19%
TTM:	1%

Stock Price CAGR
10 Years:	6%
5 Years:	7%
3 Years:	3%
1 Year:	-18%

Return on Equity
10 Years:	20%
5 Years:	16%
3 Years:	10%
Last Year:	13%

Last Updated: Unknown

Balance Sheet

Last Updated: November 15, 2024, 1:44 am

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Sep 2024
Equity Capital	38	38	38	38	38	38	38	38	39	39	39	39	39
Reserves	465	638	847	1,560	1,865	2,182	2,681	3,182	5,028	5,198	4,331	4,779	4,849
Borrowings	187	109	264	114	89	708	1,128	1,747	584	717	722	513	1,066
Other Liabilities	358	432	493	718	698	1,013	931	1,022	1,058	1,167	1,090	1,114	1,276
Total Liabilities	1,048	1,217	1,641	2,429	2,689	3,941	4,778	5,989	6,709	7,122	6,183	6,446	7,230
Fixed Assets	344	397	547	708	799	993	1,158	1,552	1,788	1,798	2,398	2,547	2,463
CWIP	32	21	83	93	396	1,010	1,551	1,846	2,183	2,304	601	524	662
Investments	3	3	2	87	50	42	49	18	236	118	96	93	102
Other Assets	668	796	1,009	1,541	1,444	1,896	2,019	2,573	2,502	2,902	3,087	3,281	4,004
Total Assets	1,048	1,217	1,641	2,429	2,689	3,941	4,778	5,989	6,709	7,122	6,183	6,446	7,230

Below is a detailed analysis of the balance sheet data for Alembic Pharmaceuticals Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

For Equity Capital, as of Sep 2024, the value is ₹39.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹39.00 Cr..
For Reserves, as of Sep 2024, the value is ₹4,849.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹4,779.00 Cr. (Mar 2024) to ₹4,849.00 Cr., marking an increase of 70.00 Cr..
For Borrowings, as of Sep 2024, the value is ₹1,066.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from ₹513.00 Cr. (Mar 2024) to ₹1,066.00 Cr., marking an increase of 553.00 Cr..
For Other Liabilities, as of Sep 2024, the value is ₹1,276.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹1,114.00 Cr. (Mar 2024) to ₹1,276.00 Cr., marking an increase of 162.00 Cr..
For Total Liabilities, as of Sep 2024, the value is ₹7,230.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹6,446.00 Cr. (Mar 2024) to ₹7,230.00 Cr., marking an increase of 784.00 Cr..
For Fixed Assets, as of Sep 2024, the value is ₹2,463.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹2,547.00 Cr. (Mar 2024) to ₹2,463.00 Cr., marking a decrease of 84.00 Cr..
For CWIP, as of Sep 2024, the value is ₹662.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹524.00 Cr. (Mar 2024) to ₹662.00 Cr., marking an increase of 138.00 Cr..
For Investments, as of Sep 2024, the value is ₹102.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹93.00 Cr. (Mar 2024) to ₹102.00 Cr., marking an increase of 9.00 Cr..
For Other Assets, as of Sep 2024, the value is ₹4,004.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹3,281.00 Cr. (Mar 2024) to ₹4,004.00 Cr., marking an increase of 723.00 Cr..
For Total Assets, as of Sep 2024, the value is ₹7,230.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹6,446.00 Cr. (Mar 2024) to ₹7,230.00 Cr., marking an increase of 784.00 Cr..

Notably, the Reserves (₹4,849.00 Cr.) exceed the Borrowings (1,066.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Cash from Operating Activity +	265	240	172	948	329	312	812	449	1,463	552	724	803
Cash from Investing Activity +	-67	-81	-256	-307	-486	-884	-756	-731	-840	-372	-448	-321
Cash from Financing Activity +	-229	-151	87	-224	-129	503	59	155	-597	-217	-262	-438
Net Cash Flow	-31	8	3	417	-286	-69	115	-127	26	-37	14	45

Free Cash Flow

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Free Cash Flow	65.00	249.00	139.00	-113.00	526.00	-65.00	873.00	0.00	-583.00	157.00	-40.00	419.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	56	54	64	40	40	61	45	69	24	56	68	60
Inventory Days	143	159	196	266	269	302	356	417	431	406	315	350
Days Payable	129	148	166	264	213	313	237	220	194	178	145	157
Cash Conversion Cycle	70	65	94	42	96	51	164	266	261	283	237	253
Working Capital Days	59	50	71	49	72	93	64	118	94	118	119	114
ROCE %	31%	44%	38%	66%	29%	22%	23%	24%	26%	11%	7%	13%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Promoters	69.61%	69.61%	69.61%	69.61%	69.61%	69.61%	69.61%	69.61%	69.61%	69.61%	69.61%	69.61%
FIIs	6.02%	5.94%	5.32%	4.99%	4.55%	4.34%	4.51%	4.52%	4.46%	4.32%	3.94%	4.17%
DIIs	11.74%	12.15%	12.55%	12.76%	13.32%	13.65%	14.22%	14.51%	15.39%	15.47%	16.05%	16.05%
Public	12.63%	12.30%	12.52%	12.64%	12.53%	12.39%	11.67%	11.36%	10.54%	10.61%	10.38%	10.17%
No. of Shareholders	1,06,437	1,01,457	1,03,811	1,01,864	99,522	97,607	89,552	85,212	76,567	74,829	91,429	93,944

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund Name	No of Shares	AUM (%)	Amount Invested (Cr)	Previous Number of Shares	Previous Date	Percentage Change
Kotak Small Cap Fund - Regular Plan	3,427,766	2.06	363.03	293,000	2025-03-11	1069.89%
DSP Mid Cap Fund	3,210,569	1.69	340.03	293,000	2025-03-11	995.76%
DSP Healthcare Fund	1,423,563	5.14	150.77	293,000	2025-03-11	385.86%
DSP Small Cap Fund	1,409,091	0.9	149.24	293,000	2025-03-11	380.92%
DSP ELSS Tax Saver Fund	1,252,667	0.76	132.67	293,000	2025-03-11	327.53%
DSP Top 100 Equity Fund	608,603	1.45	64.46	293,000	2025-03-11	107.71%
Aditya Birla Sun Life Small Cap Fund	515,665	1.04	54.61	293,000	2025-03-11	75.99%
Edelweiss Mid Cap Fund	350,586	0.5	37.13	293,000	2025-03-11	19.65%
Kotak India EQ Contra Fund - Regular Plan	293,000	0.79	31.03	293,000	2025-03-11	0%
Aditya Birla Sun Life Pharma & Healthcare Fund	240,291	2.95	25.45	293,000	2025-03-11	-17.99%

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
FaceValue	2.00	2.00	2.00	2.00	2.00
Basic EPS (Rs.)	31.33	17.40	26.50	60.81	43.97
Diluted EPS (Rs.)	31.33	17.40	26.50	60.81	43.97
Cash EPS (Rs.)	45.25	32.99	40.83	66.05	50.82
Book Value[Excl.RevalReserv]/Share (Rs.)	245.14	222.36	266.47	257.80	169.25
Book Value[Incl.RevalReserv]/Share (Rs.)	245.14	222.36	266.47	257.80	169.25
Revenue From Operations / Share (Rs.)	316.90	287.59	269.95	274.39	244.34
PBDIT / Share (Rs.)	48.93	36.18	47.04	79.75	65.14
PBIT / Share (Rs.)	35.05	22.17	32.45	70.42	56.80
PBT / Share (Rs.)	32.20	19.61	31.55	69.60	53.04
Net Profit / Share (Rs.)	31.38	18.97	26.23	56.72	42.47
NP After MI And SOA / Share (Rs.)	31.33	17.40	26.50	59.94	43.97
PBDIT Margin (%)	15.43	12.58	17.42	29.06	26.66
PBIT Margin (%)	11.06	7.70	12.02	25.66	23.24
PBT Margin (%)	10.15	6.82	11.68	25.36	21.70
Net Profit Margin (%)	9.90	6.59	9.71	20.67	17.38
NP After MI And SOA Margin (%)	9.88	6.05	9.81	21.84	17.99
Return on Networth / Equity (%)	12.78	7.82	9.94	22.97	25.74
Return on Capital Employeed (%)	13.80	9.58	11.79	25.49	25.26
Return On Assets (%)	9.55	5.53	7.31	17.56	13.83
Long Term Debt / Equity (X)	0.00	0.00	0.00	0.03	0.27
Total Debt / Equity (X)	0.08	0.14	0.12	0.03	0.54
Asset Turnover Ratio (%)	0.98	0.77	0.73	0.79	0.77
Current Ratio (X)	2.12	1.78	1.67	2.01	1.41
Quick Ratio (X)	0.98	0.87	0.72	0.85	0.72
Inventory Turnover Ratio (X)	0.89	0.86	0.78	0.93	0.95
Dividend Payout Ratio (NP) (%)	25.53	57.47	52.82	0.00	39.32
Dividend Payout Ratio (CP) (%)	17.69	31.83	34.06	0.00	33.05
Earning Retention Ratio (%)	74.47	42.53	47.18	0.00	60.68
Cash Earning Retention Ratio (%)	82.31	68.17	65.94	0.00	66.95
Interest Coverage Ratio (X)	17.11	14.17	52.15	97.85	45.21
Interest Coverage Ratio (Post Tax) (X)	11.98	8.43	30.08	70.59	32.09
Enterprise Value (Cr.)	19611.97	10301.50	15131.79	19003.45	11697.08
EV / Net Operating Revenue (X)	3.15	1.82	2.85	3.52	2.54
EV / EBITDA (X)	20.39	14.49	16.37	12.12	9.53
MarketCap / Net Operating Revenue (X)	3.10	1.72	2.75	3.52	2.18
Retention Ratios (%)	74.46	42.52	47.17	0.00	60.67
Price / BV (X)	4.01	2.23	2.78	3.70	3.12
Price / Net Operating Revenue (X)	3.10	1.72	2.75	3.52	2.18
EarningsYield	0.03	0.03	0.03	0.06	0.08

After reviewing the key financial ratios for Alembic Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 24, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 2.00.
For Basic EPS (Rs.), as of Mar 24, the value is 31.33. This value is within the healthy range. It has increased from 17.40 (Mar 23) to 31.33, marking an increase of 13.93.
For Diluted EPS (Rs.), as of Mar 24, the value is 31.33. This value is within the healthy range. It has increased from 17.40 (Mar 23) to 31.33, marking an increase of 13.93.
For Cash EPS (Rs.), as of Mar 24, the value is 45.25. This value is within the healthy range. It has increased from 32.99 (Mar 23) to 45.25, marking an increase of 12.26.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 245.14. It has increased from 222.36 (Mar 23) to 245.14, marking an increase of 22.78.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 245.14. It has increased from 222.36 (Mar 23) to 245.14, marking an increase of 22.78.
For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 316.90. It has increased from 287.59 (Mar 23) to 316.90, marking an increase of 29.31.
For PBDIT / Share (Rs.), as of Mar 24, the value is 48.93. This value is within the healthy range. It has increased from 36.18 (Mar 23) to 48.93, marking an increase of 12.75.
For PBIT / Share (Rs.), as of Mar 24, the value is 35.05. This value is within the healthy range. It has increased from 22.17 (Mar 23) to 35.05, marking an increase of 12.88.
For PBT / Share (Rs.), as of Mar 24, the value is 32.20. This value is within the healthy range. It has increased from 19.61 (Mar 23) to 32.20, marking an increase of 12.59.
For Net Profit / Share (Rs.), as of Mar 24, the value is 31.38. This value is within the healthy range. It has increased from 18.97 (Mar 23) to 31.38, marking an increase of 12.41.
For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 31.33. This value is within the healthy range. It has increased from 17.40 (Mar 23) to 31.33, marking an increase of 13.93.
For PBDIT Margin (%), as of Mar 24, the value is 15.43. This value is within the healthy range. It has increased from 12.58 (Mar 23) to 15.43, marking an increase of 2.85.
For PBIT Margin (%), as of Mar 24, the value is 11.06. This value is within the healthy range. It has increased from 7.70 (Mar 23) to 11.06, marking an increase of 3.36.
For PBT Margin (%), as of Mar 24, the value is 10.15. This value is within the healthy range. It has increased from 6.82 (Mar 23) to 10.15, marking an increase of 3.33.
For Net Profit Margin (%), as of Mar 24, the value is 9.90. This value is within the healthy range. It has increased from 6.59 (Mar 23) to 9.90, marking an increase of 3.31.
For NP After MI And SOA Margin (%), as of Mar 24, the value is 9.88. This value is within the healthy range. It has increased from 6.05 (Mar 23) to 9.88, marking an increase of 3.83.
For Return on Networth / Equity (%), as of Mar 24, the value is 12.78. This value is below the healthy minimum of 15. It has increased from 7.82 (Mar 23) to 12.78, marking an increase of 4.96.
For Return on Capital Employeed (%), as of Mar 24, the value is 13.80. This value is within the healthy range. It has increased from 9.58 (Mar 23) to 13.80, marking an increase of 4.22.
For Return On Assets (%), as of Mar 24, the value is 9.55. This value is within the healthy range. It has increased from 5.53 (Mar 23) to 9.55, marking an increase of 4.02.
For Long Term Debt / Equity (X), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 23) which recorded 0.00.
For Total Debt / Equity (X), as of Mar 24, the value is 0.08. This value is within the healthy range. It has decreased from 0.14 (Mar 23) to 0.08, marking a decrease of 0.06.
For Asset Turnover Ratio (%), as of Mar 24, the value is 0.98. It has increased from 0.77 (Mar 23) to 0.98, marking an increase of 0.21.
For Current Ratio (X), as of Mar 24, the value is 2.12. This value is within the healthy range. It has increased from 1.78 (Mar 23) to 2.12, marking an increase of 0.34.
For Quick Ratio (X), as of Mar 24, the value is 0.98. This value is below the healthy minimum of 1. It has increased from 0.87 (Mar 23) to 0.98, marking an increase of 0.11.
For Inventory Turnover Ratio (X), as of Mar 24, the value is 0.89. This value is below the healthy minimum of 4. It has increased from 0.86 (Mar 23) to 0.89, marking an increase of 0.03.
For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 25.53. This value is within the healthy range. It has decreased from 57.47 (Mar 23) to 25.53, marking a decrease of 31.94.
For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 17.69. This value is below the healthy minimum of 20. It has decreased from 31.83 (Mar 23) to 17.69, marking a decrease of 14.14.
For Earning Retention Ratio (%), as of Mar 24, the value is 74.47. This value exceeds the healthy maximum of 70. It has increased from 42.53 (Mar 23) to 74.47, marking an increase of 31.94.
For Cash Earning Retention Ratio (%), as of Mar 24, the value is 82.31. This value exceeds the healthy maximum of 70. It has increased from 68.17 (Mar 23) to 82.31, marking an increase of 14.14.
For Interest Coverage Ratio (X), as of Mar 24, the value is 17.11. This value is within the healthy range. It has increased from 14.17 (Mar 23) to 17.11, marking an increase of 2.94.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 11.98. This value is within the healthy range. It has increased from 8.43 (Mar 23) to 11.98, marking an increase of 3.55.
For Enterprise Value (Cr.), as of Mar 24, the value is 19,611.97. It has increased from 10,301.50 (Mar 23) to 19,611.97, marking an increase of 9,310.47.
For EV / Net Operating Revenue (X), as of Mar 24, the value is 3.15. This value exceeds the healthy maximum of 3. It has increased from 1.82 (Mar 23) to 3.15, marking an increase of 1.33.
For EV / EBITDA (X), as of Mar 24, the value is 20.39. This value exceeds the healthy maximum of 15. It has increased from 14.49 (Mar 23) to 20.39, marking an increase of 5.90.
For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 3.10. This value exceeds the healthy maximum of 3. It has increased from 1.72 (Mar 23) to 3.10, marking an increase of 1.38.
For Retention Ratios (%), as of Mar 24, the value is 74.46. This value exceeds the healthy maximum of 70. It has increased from 42.52 (Mar 23) to 74.46, marking an increase of 31.94.
For Price / BV (X), as of Mar 24, the value is 4.01. This value exceeds the healthy maximum of 3. It has increased from 2.23 (Mar 23) to 4.01, marking an increase of 1.78.
For Price / Net Operating Revenue (X), as of Mar 24, the value is 3.10. This value exceeds the healthy maximum of 3. It has increased from 1.72 (Mar 23) to 3.10, marking an increase of 1.38.
For EarningsYield, as of Mar 24, the value is 0.03. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 23) which recorded 0.03.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Alembic Pharmaceuticals Ltd as of March 12, 2025 is: ₹751.46

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of March 12, 2025, Alembic Pharmaceuticals Ltd is Overvalued by 11.07% compared to the current share price 845.00

Intrinsic Value of Alembic Pharmaceuticals Ltd as of March 12, 2025 is: 661.19

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of March 12, 2025, Alembic Pharmaceuticals Ltd is Overvalued by 21.75% compared to the current share price 845.00

Last 5 Year EPS CAGR: -12.01%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The stock has a high average ROCE of 27.83%, which is a positive sign. The company has higher reserves (2,892.69 cr) compared to borrowings (611.38 cr), indicating strong financial stability. The company has shown consistent growth in sales (3.62 cr) and profit (457.15 cr) over the years.	The stock has a high average Working Capital Days of 85.08, which may not be favorable. The stock has a high average Cash Conversion Cycle of 156.83, which may not be favorable.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Alembic Pharmaceuticals Ltd:
1. Net Profit Margin: 9.9%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 13.8% (Industry Average ROCE: 16%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 12.78% (Industry Average ROE: 16.32%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 11.98
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 0.98
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 28 (Industry average Stock P/E: 42.42)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0.08
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Alembic Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 16/06/2010 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is L24230GJ2010PLC061123 and registration number is 061123. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 5874.06 Cr. and Equity Capital is Rs. 39.31 Cr. for the Year ended 31/03/2024.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	Alembic Road, Vadodra Gujarat 390003	apl.investors@alembic.co.in http://www.alembicpharmaceuticals.com

Management
Name	Position Held
Mr. Chirayu Amin	Chairman & CEO
Mr. Pranav Amin	Managing Director
Mr. Shaunak Amin	Managing Director
Mr. R K Baheti	Director - Finance & CFO
Dr. Archana Hingorani	Independent Director
Mr. Ashok Barat	Independent Director
Mr. Jai Diwanji	Independent Director
Mr. Manish Kejriwal	Independent Director

FAQ

What is the latest intrinsic value of Alembic Pharmaceuticals Ltd?

The latest intrinsic value of Alembic Pharmaceuticals Ltd as on 11 March 2025 is ₹751.46, which is 11.07% lower than the current market price of 845.00, indicating the stock is overvalued by 11.07%. The intrinsic value of Alembic Pharmaceuticals Ltd is calculated using PE ratio method. The stock has a market capitalization of ₹16,603 Cr. and recorded a high/low of ₹1,304/725 during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹4,849 Cr and total liabilities of ₹7,230 Cr.

What is the Market Cap of Alembic Pharmaceuticals Ltd?

The Market Cap of Alembic Pharmaceuticals Ltd is 16,603 Cr..

What is the current Stock Price of Alembic Pharmaceuticals Ltd as on 11 March 2025?

The current stock price of Alembic Pharmaceuticals Ltd as on 11 March 2025 is ₹845.

What is the High / Low of Alembic Pharmaceuticals Ltd stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of Alembic Pharmaceuticals Ltd stocks is ₹1,304/725.

What is the Stock P/E of Alembic Pharmaceuticals Ltd?

The Stock P/E of Alembic Pharmaceuticals Ltd is 28.0.

What is the Book Value of Alembic Pharmaceuticals Ltd?

The Book Value of Alembic Pharmaceuticals Ltd is 249.

What is the Dividend Yield of Alembic Pharmaceuticals Ltd?

The Dividend Yield of Alembic Pharmaceuticals Ltd is 1.30 %.

What is the ROCE of Alembic Pharmaceuticals Ltd?

The ROCE of Alembic Pharmaceuticals Ltd is 13.1 %.

What is the ROE of Alembic Pharmaceuticals Ltd?

The ROE of Alembic Pharmaceuticals Ltd is 13.3 %.

What is the Face Value of Alembic Pharmaceuticals Ltd?

The Face Value of Alembic Pharmaceuticals Ltd is 2.00.